We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MHRA: Brexit Won’t Change EU Drug Market Access
UK drug manufacturers will retain access to EU markets during the Brexit implementation period, the MHRA said in an Aug. 6 update, noting EU authorities will continue to recognize the UK’s manufacturing and distribution licenses as well as inspections.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor